|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date28 May 2001 |
A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia
100 Clinical Results associated with Takeda Europe R Centre Ltd.
0 Patents (Medical) associated with Takeda Europe R Centre Ltd.
100 Deals associated with Takeda Europe R Centre Ltd.
100 Translational Medicine associated with Takeda Europe R Centre Ltd.